Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant neisseria meningitidis group B nhba fusion protein
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Recombinant Neisseria meningitidis group B NHBA fusion protein is a key antigenic component of the multicomponent meningococcal serogroup B vaccine, Bexsero, developed by GSK. It is a recombinant protein consisting of the Neisseria Heparin Binding Antigen (NHBA) fused to the accessory protein GNA1030. NHBA is a surface-exposed lipoprotein found in almost all strains of Neisseria meningitidis. It binds heparin, which may increase the bacterium's resistance to serum complement-mediated killing. By including this fusion protein in the vaccine, the immune system is trained to produce bactericidal antibodies that recognize and target NHBA on the surface of the bacteria, thereby facilitating their destruction and providing protection against invasive meningococcal disease caused by serogroup B.
- Brand names
- Bexsero
- Other names
- NHBA fusion proteinNeisseria Heparin Binding Antigen fusion protein
02
Targets
HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))NHBA (Neisserial heparin-binding antigen)
Beyond the preview
Go deeper on recombinant neisseria meningitidis group B nhba fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant neisseria meningitidis group B nhba fusion protein.